A dohányzással kapcsolatos genetikai és farmakogenomikai vizsgálatok összefoglalása: A nagy elemszám ára a pontatlan fenotipizálás? - Áttekinto{double acute} tanulmány

Translated title of the contribution: Genetic and pharmacogenomic data on smoking: The bigger sample size, the less reliable phenotype? A critical review

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Increasing amount of genetic data on nicotine dependence (ND) is available in the literature, sometimes extremely large population size is reported but the study design is not always consequent. Phenotypic measures can vary from a simple 6-item self-rating scale to breath CO or serum cotinine level test but in genetic investigations this is not sophisticated; moreover the population stratification is also usually ignored. In contrast, possibly because of the strict traditions of pharmacological investigations, pharmacogenomic studies on smoking cessation therapy use more reliable phenotypic measures with high quality design consequently involving fewer participants. In spite of the heavy epidemiological data on smoking in Hungary, genetic background of heavy smoking is still not studied in this population. In this review we sum up the most important, replicated results but we also provide some critical remarks about the methodological shortcomings of these studies. Keeping in mind the value of large scale population ND association studies we would also like to emphasize that the clinical implementation of studies with larger samples but with weaker methodology and statistical analyses is limited. Similar to many other psychiatric disorders, ND is a multifactorial condition, therefore the measure of genetic effects requires a more complex study design.

Original languageHungarian
Pages (from-to)7-13
Number of pages7
JournalNeuropsychopharmacologia Hungarica
Volume13
Issue number1
Publication statusPublished - Mar 2011

Fingerprint

Tobacco Use Disorder
Pharmacogenetics
Sample Size
Smoking
Phenotype
Population
Cotinine
Hungary
Smoking Cessation
Carbon Monoxide
Population Density
Psychiatry
Pharmacology
Serum
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Neuropsychology and Physiological Psychology
  • Clinical Neurology

Cite this

@article{6a63387245cf442d84def09cee750fb0,
title = "A doh{\'a}nyz{\'a}ssal kapcsolatos genetikai {\'e}s farmakogenomikai vizsg{\'a}latok {\"o}sszefoglal{\'a}sa: A nagy elemsz{\'a}m {\'a}ra a pontatlan fenotipiz{\'a}l{\'a}s? - {\'A}ttekinto{double acute} tanulm{\'a}ny",
abstract = "Increasing amount of genetic data on nicotine dependence (ND) is available in the literature, sometimes extremely large population size is reported but the study design is not always consequent. Phenotypic measures can vary from a simple 6-item self-rating scale to breath CO or serum cotinine level test but in genetic investigations this is not sophisticated; moreover the population stratification is also usually ignored. In contrast, possibly because of the strict traditions of pharmacological investigations, pharmacogenomic studies on smoking cessation therapy use more reliable phenotypic measures with high quality design consequently involving fewer participants. In spite of the heavy epidemiological data on smoking in Hungary, genetic background of heavy smoking is still not studied in this population. In this review we sum up the most important, replicated results but we also provide some critical remarks about the methodological shortcomings of these studies. Keeping in mind the value of large scale population ND association studies we would also like to emphasize that the clinical implementation of studies with larger samples but with weaker methodology and statistical analyses is limited. Similar to many other psychiatric disorders, ND is a multifactorial condition, therefore the measure of genetic effects requires a more complex study design.",
keywords = "Genetic epidemiological studies, Nicotine dependence, Pharmacogenomics, Smoking, Smoking-related phenotypes",
author = "J. Laz{\'a}ry and P. D{\"o}me and G. Faludi",
year = "2011",
month = "3",
language = "Hungarian",
volume = "13",
pages = "7--13",
journal = "Neuropsychopharmacologia Hungarica",
issn = "1419-8711",
publisher = "Hungarian Association of Psychopharmacology",
number = "1",

}

TY - JOUR

T1 - A dohányzással kapcsolatos genetikai és farmakogenomikai vizsgálatok összefoglalása

T2 - A nagy elemszám ára a pontatlan fenotipizálás? - Áttekinto{double acute} tanulmány

AU - Lazáry, J.

AU - Döme, P.

AU - Faludi, G.

PY - 2011/3

Y1 - 2011/3

N2 - Increasing amount of genetic data on nicotine dependence (ND) is available in the literature, sometimes extremely large population size is reported but the study design is not always consequent. Phenotypic measures can vary from a simple 6-item self-rating scale to breath CO or serum cotinine level test but in genetic investigations this is not sophisticated; moreover the population stratification is also usually ignored. In contrast, possibly because of the strict traditions of pharmacological investigations, pharmacogenomic studies on smoking cessation therapy use more reliable phenotypic measures with high quality design consequently involving fewer participants. In spite of the heavy epidemiological data on smoking in Hungary, genetic background of heavy smoking is still not studied in this population. In this review we sum up the most important, replicated results but we also provide some critical remarks about the methodological shortcomings of these studies. Keeping in mind the value of large scale population ND association studies we would also like to emphasize that the clinical implementation of studies with larger samples but with weaker methodology and statistical analyses is limited. Similar to many other psychiatric disorders, ND is a multifactorial condition, therefore the measure of genetic effects requires a more complex study design.

AB - Increasing amount of genetic data on nicotine dependence (ND) is available in the literature, sometimes extremely large population size is reported but the study design is not always consequent. Phenotypic measures can vary from a simple 6-item self-rating scale to breath CO or serum cotinine level test but in genetic investigations this is not sophisticated; moreover the population stratification is also usually ignored. In contrast, possibly because of the strict traditions of pharmacological investigations, pharmacogenomic studies on smoking cessation therapy use more reliable phenotypic measures with high quality design consequently involving fewer participants. In spite of the heavy epidemiological data on smoking in Hungary, genetic background of heavy smoking is still not studied in this population. In this review we sum up the most important, replicated results but we also provide some critical remarks about the methodological shortcomings of these studies. Keeping in mind the value of large scale population ND association studies we would also like to emphasize that the clinical implementation of studies with larger samples but with weaker methodology and statistical analyses is limited. Similar to many other psychiatric disorders, ND is a multifactorial condition, therefore the measure of genetic effects requires a more complex study design.

KW - Genetic epidemiological studies

KW - Nicotine dependence

KW - Pharmacogenomics

KW - Smoking

KW - Smoking-related phenotypes

UR - http://www.scopus.com/inward/record.url?scp=79955883318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955883318&partnerID=8YFLogxK

M3 - Article

C2 - 21451187

AN - SCOPUS:79955883318

VL - 13

SP - 7

EP - 13

JO - Neuropsychopharmacologia Hungarica

JF - Neuropsychopharmacologia Hungarica

SN - 1419-8711

IS - 1

ER -